

A. Randomized Controlled Trials (n=8)



B. Non-randomized Controlled Trials / Before-after studies (n=59)

Supplementary Figure 2: Risk of bias of the experimental studies included in the immunogenicity analysis

[a] Representativeness based on the description of the source population, the representativeness of the eligible population, the inclusion criteria and the percentage of participation.
[b] Selection of the compared groups from the same source and the response rate.
[c] Blinding of study participants and personnel or no impact on the results
[d] Comparability of administered vaccine, time since vaccination, risk of exposure to measles, malnutrition and no control for maternal antibodies.
[e] Completeness of outcome data.
[f] Information bias assessment based on same vaccine strain and potency administered to all participants and laboratory method to detect antibodies.
[g] Possibility of selective outcome reporting